Clinical data
Routes of
ATC code none
Legal status
Legal status
  • Uncontrolled
CAS Number 220322-05-4 YesY
PubChem (CID) 19544192
CID 6914152
ChemSpider 5290108
UNII 933PJL964R YesY
Chemical and physical data
Formula C22H23Cl2N3OS
Molar mass 448.4085 g/mol
3D model (Jmol) Interactive image

Elzasonan (CP-448,187) is a selective 5-HT1B and 5-HT1D receptor antagonist that was under development by Pfizer for the treatment of depression but was discontinued, possibly due to poor efficacy.[1][2][3][4][5] By preferentially blocking 5-HT1B and 5-HT1D autoreceptors, elzasonan is thought to enhance serotonergic innervations originating from the raphe nucleus, thereby improving signaling to limbic regions like the hippocampus and prefrontal cortex and ultimately resulting in antidepressant effects.[3]

See also


This article is issued from Wikipedia - version of the 10/30/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.